Intestinal Microbiota, Leaky Gut Syndrome and New Interpretation of Pathogenesis and Prophylaxis of Well-Known Diseases (Review)

Ukrainets R. V.
Pathologist, V.G. Molotkov Department of Clinical Pathology No. 2¹; Assistant, Chair for Pathological Anatomy²

Korneva Yu. S.
MD, PhD, Assistant Professor, Chair for Pathological Anatomy²; Pathologist, V.G. Molotkov Department of Clinical Pathology No. 2¹

1 - Smolensk State Medical University, Smolensk, Russia
2 - Smolensk Regional Institute of Pathology, Smolensk, Russia

Korneva Yulia; e-mail: ksu1546@yandex.ru

None declared.

The study had no sponsorship.

The review describes intestinal microbiota as a complicated system, that has great impact on regulation of homeostasis in human body, attention is paid to factors, capable of disturbing it. Symbiosis between microbiota and host and disturbing is a subject for discussion, essential for understanding of homeostasis regulation. Changes in mircobiota quality and quantity (dysbacteriosis) lead to leaky gut syndrome formation. Prolonged and stable disturbances, related to onset of this newly described syndrome, nowadays are described as etiopathogenetic steppingstone for many well-known diseases, especially with unclear etiology and pathogenesis. Scientists investigate interaction between microbiota and host searching for new methods for microbiota influence on host. That’s why, estimation of intestinal microbiota may be used for diagnostic purposes, helping to determine risks of pathology onset to perform prevention measures, or it may reflect possible stage of existing disease and become the possible target in treatment of many outcomes.

microbiota, dysbacteriosis, leaky gut syndrome

10.29234/2308-9113-2020-8-1-20-33

1. Dinan T.G., Cryan J.F. Regulation of the stress response by the gut microbiota: implications for psychoneuroendocrinology. Psychoneuroendocrinology 2012; 37(9): 1369-78. doi: 10.1016/j.psyneuen.2012.03.007

2. Li J.Y., Chassaing B., Tyagi A.M., Vaccaro C., Luo T., Adams J., Darby T.M., Weitzmann M.N., Mulle J.G., Gewirtz A.T., Jones R.M., Pacifici R. Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics. J Clin Invest. 2016;.126(6): 2049-63. doi: 10.1172/JCI86062

3. Muraca M., Putignani L., Fierabracci A., Teti A., Perilongo G. Gut microbiota-derived outer membrane vesicles: under-recognized major players in health and disease? Discov Med. 2015; 19(106): 343-8.

4. Wells J.M., Brummer R.J., Derrien M., MacDonald T.T., Troost F., Cani P.D., Theodorou V., Dekker J., Méheust A., de Vos W.M., Mercenier A., Nauta A., Garcia-Rodenas C.L. Homeostasis of the gut barrier and potential biomarkers. Am J Physiol Gastrointest Liver Physiol. 2017; 312(3): G171-G193. doi: 10.1152/ajpgi.00048.2015.

5. Zheng L., Kelly C.J., Battista K.D., Schaefer R., Lanis J.M., Alexeev E.E., Wang R.X., Onyiah J.C., Kominsky D.J., Colgan S.P. Microbial-Derived Butyrate Promotes Epithelial Barrier Function through IL-10 Receptor-Dependent Repression of Claudin-2. J Immunol. 2017; 199(8): 2976-2984. doi: 10.4049/jimmunol.1700105.

6. Nutsch K., Chai J.N., Ai T.L., Russler-Germain E., Feehley T., Nagler C.R., Hsieh C.S. Rapid and Efficient Generation of Regulatory T Cells to Commensal Antigens in the Periphery. Cell Rep. 2016; 17(1): 206-220. doi: 10.1016/j.celrep.2016.08.092.

7. Laschke M.W., Menger M.D. The gut microbiota: a puppet master in the pathogenesis of endometriosis? Am J Obstet Gynecol. 2016; 215(1): 68.e1-4. doi: 10.1016/j.ajog.2016.02.036.

8. Cani P.D., Possemiers S., Van de Wiele T., Guiot Y., Everard A., Rottier O., Geurts L., Naslain D., Neyrinck A., Lambert D.M., Muccioli G.G., Delzenne N.M. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009; 58(8): 1091-103. doi: 10.1136/gut.2008.165886.

9. Diehl G.E., Longman R.S., Zhang J.X., Breart B., Galan C., Cuesta A., Schwab S.R., Littman D.R. Microbiota restricts trafficking of bacteria to mesenteric lymph nodes by CX(3)CR1(hi) cells. Nature 2013; 494(7435): 116-20. doi: 10.1038/nature11809.

10. Margry B., Wieland W.H., van Kooten P.J., van Eden W., Broere F. Peritoneal cavity B-1a cells promote peripheral CD4+ T-cell activation. Eur J Immunol. 2013; 43(9): 2317-26. doi: 10.1002/eji.201343418.

11. Emani R., Alam C., Pekkala S., Zafar S., Emani M.R., Hänninen A. Peritoneal cavity is a route for gut-derived microbial signals to promote autoimmunity in non-obese diabetic mice. Scand J Immunol. 2015; 81(2): 102-9. doi: 10.1111/sji.12253.

12. Knoop K.A., McDonald K.G., Kulkarni D.H., Newberry R.D. Antibiotics promote inflammation through the translocation of native commensal colonic bacteria. Gut 2016; 65(7): 1100-9. doi: 10.1136/gutjnl-2014-309059.

13. Dasgupta S., Kasper D.L. Traffic control at the «Gut-GALT crossroads». Cell Res. 2013; 23(5): 590-1. doi: 10.1038/cr.2013.4.

14. Fonseca D.M., Hand T.W., Han S.J., Gerner M.Y., Glatman Zaretsky A., Byrd A.L., Harrison O.J., Ortiz A.M., Quinones M., Trinchieri G., Brenchle J.M., Brodsky I.E., Germain R.N., Randolph G.J., Belkaid Y. Microbiota-Dependent Sequelae of Acute Infection Compromise Tissue-Specific Immunity. Cell 2015; 163(2): 354-66. doi: 10.1016/j.cell.2015.08.030.

15. McGough G. Leaky Gut. Nurs Stand. 2011; 25(51): 30. doi: 10.7748/ns2011.08.25.51.30.p6185.

16. Karl J.P., Margolis L.M., Madslien E.H., Murphy N.E., Castellani J.W., Gundersen Y., Hoke A.V., Levangie M.W., Kumar R., Chakraborty N., Gautam A., Hammamieh R., Martini S., Montain S.J., Pasiakos S.M.. Changes in intestinal microbiota composition and metabolism coincide with increased intestinal permeability in young adults under prolonged physiological stress. Am J Physiol Gastrointest Liver Physiol. 2017; 312(6): G559-G571. doi: 10.1152/ajpgi.00066.2017.

17. Thevaranjan N., Puchta A., Schulz C., Naidoo A., Szamosi J.C., Verschoor C.P., Loukov D., Schenck L.P., Jury J., Foley K.P., Schertzer J.D., Larché M.J., Davidson D.J., Verdú E.F., Surette M.G., Bowdish D.M.E. Age-Associated Microbial Dysbiosis Promotes Intestinal Permeability, Systemic Inflammation, and Macrophage Dysfunction. Cell Host Microbe. 2017; 21(4): 455-466.e4. doi: 10.1016/j.chom.2017.03.002

18. Leclercq S., Cani P.D., Neyrinck A.M., Stärkel P., Jamar F., Mikolajczak M., Delzenne N.M., de Timary P. Role of intestinal permeability and inflammation in the biological and behavioral control of alcohol-dependent subjects. Brain Behav Immun. 2012; 26(6): 911-8. doi: 10.1016/j.bbi.2012.04.001.

19. Qin X., Deitch E.A. Dissolution of lipids from mucus: a possible mechanism for prompt disruption of gut barrier function by alcohol. Toxicol Lett. 2015; 232(2): 356-62. doi: 10.1016/j.toxlet.2014.11.027.

20. Leclercq S., Matamoros S., Cani P.D., Neyrinck A.M., Jamar F., Stärkel P., Windey K., Tremaroli V., Bäckhed F., Verbeke K., de Timary P., Delzenne N.M. Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc Natl Acad Sci U S A. 2014; 111(42): E4485-93. doi: 10.1073/pnas.1415174111.

21. Odenwald M.A., Turner J.R. Intestinal permeability defects: is it time to treat? Clin Gastroenterol Hepatol. 2013; 11(9): 1075-83. doi: 10.1016/j.cgh.2013.07.001.

22. Sun M., He C., Cong Y., Liu Z. Regulatory immune cells in regulation of intestinal inflammatory response to microbiota. Mucosal Immunol. 2015; 8(5): 969-978. doi: 10.1038/mi.2015.49.

23. Michielan A., D'Incà R. Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut. Mediators Inflamm. 2015; 2015: 628157. doi: 10.1155/2015/628157.

24. Liu Z., Li N., Neu J. Tight junctions, leaky intestines, and pediatric diseases. Acta Paediatr. 2005; 94(4): 386-93.

25. Mu Q., Kirby J., Reilly C.M., Luo X.M. Leaky Gut as a Danger Signal for Autoimmune Diseases. Front Immunol. 2017;.8:598. doi: 10.3389/fimmu.2017.00598.

26. Valentini L., Ramminger S., Haas V., Postrach E., Werich M., Fischer A., Koller M., Swidsinski A., Bereswill S., Lochs H., Schulzke J.D. Small intestinal permeability in older adults. Physiol Rep. 2014; 22; 2(4): e00281. doi: 10.14814/phy2.281.

27. McFarlin B.K,. Henning A.L., Bowman E.M., Gary M.A., Carbajal K.M. Oral spore-based probiotic supplementation was associated with reduced incidence of post-prandial dietary endotoxin, triglycerides, and disease risk biomarkers. World J Gastrointest Pathophysiol. 2017; 8(3): 117-126. doi: 10.4291/wjgp.v8.i3.117.

28. Nakata K., Yamamoto M., Inagawa H., Soma G. Effects of interactions between intestinal microbiota and intestinal macrophages on health. Anticancer Res. 2013; 33(7): 2849-53.

29. Takiishi T., Fenero C.I.M., Câmara N.O.S. Intestinal barrier and gut microbiota: Shaping our immune responses throughout life. Tissue Barriers 2017; 5(4): e1373208. doi: 10.1080/21688370.2017.1373208.

30. Caputi V., Marsilio I., Filpa V., Cerantola S., Orso G., Bistoletti M., Paccagnella N., De Martin S., Montopoli M., Dall'Acqua S., Crema F., Di Gangi I.M., Galuppini F., Lante I., Bogialli S., Rugge M., Debetto P., Giaroni C., Giron M.C. Antibiotic-induced dysbiosis of the microbiota impairs gut neuromuscular function in juvenile mice. Br J Pharmacol. 2017; 174(20): 3623-3639. doi: 10.1111/bph.13965.

31. Lin R., Zhou L., Zhang J., Wang B. Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis. Int J Clin Exp Pathol. 2015; 8(5): 5153-60.

32. Muraca M., Putignani L., Fierabracci A., Teti A., Perilongo G. Gut microbiota-derived outer membrane vesicles: under-recognized major players in health and disease? Discov Med. 2015; 19(106): 343-8.

33. Bonaz В., Bazin T., Pellissier S. The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis. Front Neurosci. 2018; 12: 49. doi: 10.3389/fnins.2018.00049.

34. Obrenovich M.E.M. Leaky Gut, Leaky Brain? Microorganisms. 2018;6(4). pii: E107. doi: 10.3390/microorganisms6040107.

35. Anderson G., Seo M., Berk M., Carvalho A.F., Maes M. Gut Permeability and Microbiota in Parkinson's Disease: Role of Depression, Tryptophan Catabolites, Oxidative and Nitrosative Stress and Melatonergic Pathways. Curr Pharm Des. 2016; 22(40): 6142-6151.

36. Van Hemert S., Breedveld A.C., Rovers J.M., Vermeiden J.P., Witteman B.J., Smits M.G., de Roos N.M. Migraine associated with gastrointestinal disorders: review of the literature and clinical implications. Front Neurol. 2014; 5: 241. doi: 10.3389/fneur.2014.00241.

37. Straube A., Müller H., Stiegelbauer V., Frauwallner A. Migraine prophylaxis with a probiotic. Results of an uncontrolled observational study with 1,020 patients. MMW Fortschr Med. 2018; 160(Suppl 5): 16-21. doi: 10.1007/s15006-018-1052-5.

38. Mandarano A.H., Giloteaux L., Keller B.A., Levine S.M., Hanson M.R. Eukaryotes in the gut microbiota in myalgic encephalomyelitis/chronic fatigue syndrome. PeerJ. 2018; 6: e4282. doi: 10.7717/peerj.4282.

39. Maes M., Coucke F., Leunis J.C. Normalization of the increased translocation of endotoxin from gram negative enterobacteria (leaky gut) is accompanied by a remission of chronic fatigue syndrome. Neuro Endocrinol Lett. 2007; 28(6): 739-44.

40. Fowlie G., Cohen N., Ming X. The Perturbance of Microbiome and Gut-Brain Axis in Autism Spectrum Disorders. Int J Mol Sci. 2018; 19(8). pii: E2251. doi: 10.3390/ijms19082251.

41. Maes M., Kubera M., Leunis J.C., Berk M. Increased IgA and IgM responses against gut commensals in chronic depression: further evidence for increased bacterial translocation or leaky gut. J Affect Disord. 2012; 141(1): 55-62. doi: 10.1016/j.jad.2012.02.023.

42. Karakuła-Juchnowicz H., Dzikowski M., Pelczarska A., Dzikowska I., Juchnowicz D. The brain-gut axis dysfunctions and hypersensitivity to food antigens in the etiopathogenesis of schizophrenia. Psychiatr Pol. 2016; 50(4): 747-760. doi: 10.12740/PP/OnlineFirst/45053.

43. Kanchanatawan B., Sirivichayakul S., Thika S., Ruxrungtham K., Carvalho A.F., Geffard M., Anderson G., Noto C., Ivanova R., Maes M. Physio-somatic symptoms in schizophrenia: association with depression, anxiety, neurocognitive deficits and the tryptophan catabolite pathway. Metab Brain Dis. 2017; 32(4): 1003-1016. doi: 10.1007/s11011-017-9982-7.

44. Barbara G., Zecchi L., Barbaro R., Cremon C., Bellacosa L., Marcellini M., De Giorgio R., Corinaldesi R., Stanghellini V. Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome. J Clin Gastroenterol. 2012; 46 (Suppl): S52-5. doi: 10.1097/MCG.0b013e318264e918.

45. Lopetuso L.R., Scaldaferri F., Bruno G., Petito V., Franceschi F., Gasbarrini A. The therapeutic management of gut barrier leaking: the emerging role for mucosal barrier protectors. Eur Rev Med Pharmacol Sci. 2015; 19(6): 1068-76.

46. Viganò D., Zara F., Usai P. Irritable bowel syndrome and endometriosis: New insights for old diseases. Dig Liver Dis. 2018; 50(3): 213-219. doi: 10.1016/j.dld.2017.12.017.

47. Yuan M., Li D., Zhang Z., Sun H., An M., Wang G. Endometriosis induces gut microbiota alterations in mice. Hum Reprod. 2018; 33(4): 607-616. doi: 10.1093/humrep/dex372.

48. Lindheim L., Bashir M., Münzker J., Trummer C., Zachhuber V., Leber B., Horvath A., Pieber T.R., Gorkiewicz G., Stadlbauer V., Obermayer-Pietsch B. Alterations in Gut Microbiome Composition and Barrier Function Are Associated with Reproductive and Metabolic Defects in Women with Polycystic Ovary Syndrome(PCOS): A Pilot Study. PLoS One. 2017; 12(1): e0168390. doi: 10.1371/journal.pone.0168390.

49. Fändriks L. Roles of the gut in the metabolic syndrome: an overview. J Intern Med. 2017; 281(4): 319-336. doi: 10.1111/joim.12584.

50. Cox A.J., West N.P., Cripps A.W. Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol. 2015; 3(3): 207-15. doi: 10.1016/S2213-8587(14)70134-2.

51. Saggioro A. Leaky gut, microbiota, and cancer: an incoming hypothesis. J Clin Gastroenterol. 2014; 48(Suppl): S62-6. doi: 10.1097/MCG.0000000000000255.

52. Andriessen E.M., Wilson A.M., Mawambo G., Dejda A., Miloudi K., Sennlaub F., Sapieha P. Gut microbiota influences pathological angiogenesis in obesity-driven choroidal neovascularization. EMBO Mol Med. 2016; 8(12): 1366-1379. doi: 10.15252/emmm.201606531.